Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Oral anticoagulants (OACs) effectively reduce the risk of stroke in atrial fibrillation (AF). Three non-vitamin K antagonist OACs (NOACs) are introduced in regular care based on promising results compared with warfarin in randomized trials. This study compares outcomes with NOAC vs. warfarin treatment in OAC naïve AF patients in routine care, including primary care, in a large region with decentralized anticoagulant treatment.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Europace

Title: Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology

Publisher: Oxford University Press (OUP)

ISSN (Electronic): 1532-2092

ISSN (Print): 1099-5129

Publication date (Electronic): March 01 2018

Volume: 20

Issue: 3

Affiliations

[1 ] Clinical Epidemiology/Clinical Pharmacology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital Solna, SE-171 76 Stockholm, Sweden.

[2 ] Department of Healthcare Development, Stockholm County Council, Public Healthcare Services Committee, Karolinska University Hospital Solna, Stockholm, Sweden.

[3 ] Department of Medicine Solna, Centre for Pharmacoepidemiology, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden.

Article

Publisher Item ID: 2978055

DOI: 10.1093/europace/euw416

PubMed ID: 28177459

SO-VID: f9c4332b-7ea6-4847-9e7b-3bd8d0a9695b

History

Data availability:

Comments

Comment on this article

scite_

Cited by 28

See all cited by